Core Viewpoint - Warner Pharmaceuticals announced participation in the national organized procurement for drugs, with 12 products expected to be selected, including Montmorillonite Powder and Mycophenolate Mofetil Capsules [1] Group 1: Procurement Details - The procurement cycle will last from the actual execution date of the selection results until December 31, 2028 [1] - The projected sales revenue for selected products in 2024 is 176.18 million yuan, accounting for 12.47% of the annual revenue [1] - For the period from January to September 2025, the expected sales revenue is 192.05 million yuan, representing 17.69% of the revenue during the same period [1] Group 2: Future Implications - If procurement contracts are signed and executed, it will expand the sales scale of the products [1] - There is uncertainty regarding the signing of procurement contracts and the execution of market sales [1]

Core Viewpoint - Zhuohe Pharmaceutical Group Co., Ltd. is a comprehensive enterprise focusing on drug research and development, sales, and marketing authorization holder (MAH), with a strategy that combines raw materials and formulations, innovative drugs, and specialty generics, aiming for both domestic and global markets [1] Group 1: Talent and Innovation - Talent is a strong driving force for innovation in the biopharmaceutical sector, and the company has implemented a comprehensive employee quality improvement system, including business training and skill competitions [2] - The company has established a "1+1" mentor training model to cultivate young talents and has recognized several individuals as high-level innovative talents at various governmental levels [2] - The head of the R&D analysis department has led the team to overcome challenges in multiple new drug projects and has been recognized for her contributions, including a national invention patent [2] Group 2: Innovation System - The company emphasizes that R&D innovation is the source of its development and has established several provincial-level research centers and specialized R&D platforms [3] - Currently, the company has over 70 ongoing research projects in various disease areas and has received 22 domestic and international invention patents, with over 100 patent applications filed [3] - Notable achievements include the approval of a traditional Chinese medicine innovative drug and the advancement of a new generation JAK1 selective inhibitor into phase III clinical trials [3] Group 3: Global Market Expansion - Zhuohe Pharmaceutical is actively expanding its international business, with 13 raw material products certified in major markets, including the U.S., EU, and Japan [4] - The company has achieved significant market presence, with its raw material product, Neomycin sulfate, holding over 50% of the global high-end market [4] - Recent milestones include FDA registration for its oral formulation workshop and the approval of a new drug application for a specific capsule, marking entry into mainstream international markets [4]